TORL BioTherapeutics Presents Updated Phase 1 Results of Novel Claudin 6 Targeted ... - BioSpace
TORL-1-23, an ADC targeting CLDN6, shows clinically meaningful responses and manageable safety in CLDN6+ platinum-resistant ovarian cancer patients. A Phase 2 study is planned for registration-enabling, while expansion cohorts in ovarian, NSCLC, and other CLDN6+ cancers continue in the Phase 1 trial.
Related Clinical Trials
Reference News
TORL BioTherapeutics Presents Updated Phase 1 Results of Novel Claudin 6 Targeted ... - BioSpace
TORL-1-23, an ADC targeting CLDN6, shows clinically meaningful responses and manageable safety in CLDN6+ platinum-resistant ovarian cancer patients. A Phase 2 study is planned for registration-enabling, while expansion cohorts in ovarian, NSCLC, and other CLDN6+ cancers continue in the Phase 1 trial.